Here are the key takeaways:
– The drug was initially authorized for temporary emergency treatment for COVID-19, but has now been officially approved
– The drug is administered via an IV only in the hospital
– The majority of patients treated with remdesivir receive a five-day treatment course using six vials of intravenous the drug
– The company is also developing an inhaled version of the drug, which it will administer through a nebulizer
– The company has said the drug can’t be administered in pill form because its chemical properties would impact the liver
– The drug is also known as Veklury
– As the world awaits the vaccine for coronavirus, the approval of remdesivir leads a path to a promising future.
